Trump’s Drug Pricing Plan May Raise—Not Lower—US Costs: Official

WASHINGTON — The Trump administration’s ambitious plan to lower prescription drug prices in the United States may hinge on a counterintuitive strategy: encouraging higher prices for new medications in other wealthy countries. Recent comments from Chris Klomp, Director of Medicare at the Centers for Medicare and Medicaid Services (CMS), reveal a core assumption of the “most favored nation” (MFN) pricing model – that manufacturers will be allowed, even incentivized, to raise prices internationally, so long as the U.S. Isn’t undercut.

The strategy, outlined during STAT’s Breakthrough Summit East in New York, raises questions about the long-term viability of the MFN approach and its potential impact on global drug access. Klomp stated the administration essentially told manufacturers, “price wherever you want,” with the sole stipulation that U.S. Prices not be lower than those offered in other developed nations. STAT News reported on the exchange.

The MFN Framework and its Temporal Limits

The MFN model, a cornerstone of President Trump’s efforts to tackle high drug costs, aims to tie U.S. Drug prices to the lowest price offered in a select group of comparable countries. The administration has already secured agreements with several pharmaceutical companies – Pfizer, AstraZeneca, EMD Serono, Eli Lilly and Novo Nordisk – to implement MFN pricing for specific medications, including GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The Academy of Managed Care Pharmacy provides an overview of these agreements.

However, the timeline is critical. As STAT News previously reported, these deals are typically structured with three-year terms. This means that by the time companies fully launch new drugs internationally and adjust pricing accordingly, the current MFN agreements could expire, and a new administration might be in power, potentially dismantling the entire framework. The reliance on manufacturers raising prices abroad to maintain the system’s integrity introduces a significant degree of uncertainty.

GLP-1s: A Case Study in Direct-to-Consumer Pricing

The recent agreements surrounding GLP-1 medications, used for both diabetes and weight management, illustrate the complexities of the MFN approach. Manufacturers have agreed to offer these drugs on the TrumpRx platform for an average monthly price of $350 for vials. This represents a 30% discount compared to the $499 per month currently charged through direct-to-consumer platforms offered by the manufacturers themselves for Wegovy and Zepbound.

manufacturers have committed to pricing starting doses of oral GLP-1 formulations at $150 per month, should they receive FDA approval for chronic weight management. Klomp indicated that manufacturers have also agreed to align the price of injectable GLP-1s with Medicare and Medicaid pricing over the next 24 months. This suggests a phased implementation of the MFN model, with varying timelines for different drug classes and delivery methods.

What Does This Signify for U.S. Consumers?

The administration’s strategy is predicated on the idea that by preventing other countries from securing significantly lower prices, it can maintain or even increase revenue for pharmaceutical companies, allowing them to offer lower prices in the U.S. Without substantially impacting their bottom line. However, this assumes that manufacturers will willingly accept higher prices in other markets. It also doesn’t address the underlying factors driving high drug costs in the U.S., such as patent protections, marketing expenses, and the complexities of the U.S. Healthcare system.

The potential for increased prices abroad raises ethical concerns about access to essential medicines in other countries. If manufacturers are compelled to raise prices in these markets to satisfy the MFN requirements, it could limit affordability and access for patients in those regions. This could disproportionately affect individuals in lower-income countries or those without adequate health insurance coverage.

The Role of Medicare and Medicaid

The involvement of Medicare and Medicaid is central to the MFN strategy. Klomp’s statement that manufacturers have agreed to lower prices for injectable GLP-1s to the level offered to these government programs underscores the administration’s focus on leveraging the purchasing power of the federal government to negotiate lower drug prices. This approach aligns with broader efforts to reform Medicare drug pricing, including proposals to allow Medicare to directly negotiate prices with pharmaceutical companies.

However, the success of this strategy depends on the continued cooperation of pharmaceutical manufacturers and the ability of the administration to enforce the MFN agreements. Any legal challenges or resistance from the industry could jeopardize the implementation of the plan. The Reuters reports that the U.S. Has begun engaging drugmakers to put Trump’s MFN pricing into law, suggesting a push for legislative backing to solidify the policy.

What Comes Next: Policy Implementation and Potential Challenges

The coming months will be crucial for the implementation of the MFN drug pricing model. The administration will require to finalize the details of the agreements with pharmaceutical companies, establish mechanisms for monitoring compliance, and address any legal challenges that may arise. The White House is currently pitching the draft to pharmaceutical companies, according to The Washington Post.

the political landscape could shift significantly in the lead-up to the next presidential election, potentially impacting the future of the MFN plan. A change in administration could lead to a reversal of the policy or a renegotiation of the agreements with pharmaceutical companies. The long-term success of the MFN model will ultimately depend on its ability to withstand political and legal challenges and deliver tangible benefits to U.S. Consumers without compromising access to medicines in other countries.